about
Smoking, Alcohol, Drug Use, Abuse and Dependence in Narcolepsy and Idiopathic Hypersomnia: A Case-Control StudyAbsence of NMDA receptor antibodies in the rare association between Type 1 Narcolepsy and Psychosis.Treatment Options for Narcolepsy.Management of Narcolepsy.Hypersomnolence, Hypersomnia, and Mood Disorders.Narcolepsy and Other Central Hypersomnias.Comorbidity between central disorders of hypersomnolence and immune-based disorders.[18F]Fludeoxyglucose-Positron Emission Tomography Evidence for Cerebral Hypermetabolism in the Awake State in Narcolepsy and Idiopathic Hypersomnia.Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment.Measurement of narcolepsy symptoms: The Narcolepsy Severity Scale.Diagnostic criteria for disorders of arousal: A video-polysomnography assessment.Alternative diagnostic criteria for idiopathic hypersomnia: A 32-hour protocol.Effect of psychostimulants on blood pressure profile and endothelial function in narcolepsy.Test-Retest Reliability of the Multiple Sleep Latency Test in Central Disorders of Hypersomnolence.Depression and Hypersomnia: A Complex Association.Temporal Changes in the Cerebrospinal Fluid Level of Hypocretin-1 and Histamine in Narcolepsy.Vitamin D deficiency in type 1 narcolepsy: a reappraisal.Preliminary results on CSF biomarkers for hypothalamic dysfunction in Kleine-Levin syndrome.Absence of γ-aminobutyric acid-a receptor potentiation in central hypersomnolence disorders.[CLINICAL INVESTIGATION OF AN EXCESSIVE SLEEPINESS COMPLAINT].Cardiac Sympathetic Activity differentiates Idiopathic and Symptomatic Rapid Eye Movement Sleep Behaviour Disorder.Exploring the clinical features of narcolepsy type 1 versus narcolepsy type 2 from European Narcolepsy Network database with machine learningPersistence of deep-tendon reflexes during partial cataplexyReduced brain amyloid burden in elderly patients with narcolepsy type 1Neural network analysis of sleep stages enables efficient diagnosis of narcolepsy[Sleep disorders in children and adults]Author response: Comorbidity between central disorders of hypersomnolence and immune-based disordersExploration of cardiac sympathetic adrenergic nerve activity in narcolepsy[Normal organization of sleep and its changes during life]Recent advances in treatment for narcolepsyIncreased blood pressure during the suggested immobilization test in Restless Legs SyndromeClinical neurophysiology of CNS hypersomniasMeasurement of symptoms in idiopathic hypersomnia: The Idiopathic Hypersomnia Severity ScaleValidation of Multiple Sleep Latency Test for the diagnosis of pediatric narcolepsy type 1Clinical autonomic dysfunction in narcolepsy type 1Shared T cell receptor chains in blood memory CD4+ T cells of narcolepsy type 1 patientsCSF and serum ferritin levels in narcolepsy type 1 comorbid with restless legs syndrome
P50
Q36606342-5E581048-12FB-4E71-838C-713340940C79Q36865000-1BD1E996-0F89-4695-B8CA-DC8AD06A4405Q38828355-64C83489-026B-444D-A970-1A71E7612051Q38828918-CFB2EDF8-9283-45DC-A16F-38385E07389DQ39153990-A1662916-DBB4-4F39-B20D-90697D6E9E8AQ40106623-7E931E35-B8B4-4094-AADF-D0A6F6D37287Q40467274-F95EBE9C-7C25-4DE9-A2E3-638D42D20D75Q41061446-E8C19DC1-6A6C-4B9E-9942-7EED868AA949Q41995022-B1FCE992-394D-4D80-A5D4-73122D8F7A85Q47572037-02A1103D-B7E6-464D-8067-C190949776FFQ47642124-B893B4C4-CE93-454C-882B-BB0DE2A83163Q47646325-0894F2F1-FD9F-485B-8E3F-E1BA1C4D8932Q47646597-8BF1B95E-7D3C-41E1-94FC-EA9986FDB12BQ47666425-650FA1B2-BEB1-47FA-AF91-CF9BBDE1A832Q47700513-7459F765-23FC-4D2D-954D-389C90466EB0Q47747609-7A561C8E-36B0-464F-A9EC-9E79974E1790Q47768155-C6811392-F933-4FB1-8983-6DD574AD1303Q48011799-2E75B2E0-04AA-4319-9171-B028A2B2AB78Q48548130-734E6924-D440-4467-AC0E-914CE9036EABQ53722817-C8DC46C7-CFFD-433A-903F-BB733812051BQ55339224-09B72EC5-DC89-40FC-B0EB-7F8924AC0333Q56366124-6326B3BC-17B1-4A87-BFF5-540F5A41D659Q56384441-2CC9BD73-B28E-439C-A74F-2BB43F3D494CQ58615299-286D1D43-E7F3-440B-A641-413482084ADEQ59755770-87CB5A3B-5FE0-481C-865E-29D17C76904BQ86294726-2AF6CFFF-0CEE-4BCC-924C-B673942C88FCQ87969368-4F7A65FD-1B49-4180-8AE8-4F06A3D54DEDQ90679452-F28EB35E-95A9-4E2A-B646-F1D277813B1DQ90795698-595CCB26-2F75-4474-B310-11D266C721DAQ90837345-892EF89C-48B4-4714-BB47-B23DBDB16E8EQ90891561-7E733DD4-E287-4CA3-BD3E-AC9DFED8C17BQ91896815-9CAB8BA9-42AF-4E3D-A0B1-26F11A2B8D23Q92339848-B19599F8-2654-4F62-84C4-4BF324463894Q92575907-3D8E61E9-DCD8-4BCF-B82C-91CE8097605BQ92653627-91053340-505A-4CD0-A41C-4837D080E103Q92857365-24CDDC21-4EF4-416D-9377-878DEE828E77Q95304072-285DBF1D-9EF7-4EBB-A94A-12827CDA8E4A
P50
description
investigador
@es
researcher
@en
name
Lucie Barateau
@en
type
label
Lucie Barateau
@en
prefLabel
Lucie Barateau
@en
P31
P496
0000-0002-6620-5127